We evaluated the capacity of GEN1046 to enhance T-cell–mediated cytotoxicity of PD-L1–expressing tumor cells by coculturing CLDN6-TCR+ CD8+ T cells (preactivated to induce 4-1BB expression) with CLDN6+ PD-L1+ MDA-MB-231 target cells in the presence of GEN1046 or clinical-grade PD-(L)1–blocking agents. The gene discussed is CD8A; the disease is neoplasm.